Embleema Inc. announces the formation of its Advisory Board and the appointment of three members effective immediately: Adel B. Al-Saleh, Member of the Board of Management of Deutsche Telekom AG and CEO of T-Systems; Frédéric Duchesne, CEO of Pierre Fabre Pharmaceuticals; and Bernard Gilly, Ph.D., Founder and President of iBioNext.
“I am humbled and grateful to have Adel, Bernard and Frédéric join our Advisory Board,” said Robert Chu, Founder and CEO of Embleema Inc., “Each one of them is a globally recognized leader in their respective area and have an impressive track record of growing billion-dollar businesses. Having Adel, Bernard and Frédéric in our Advisory Board will provide us a tremendous advantage in articulating and executing our growth strategy.”
Before being appointed Member of the Board of Management of Deutsche Telekom AG and CEO of T-Systems effective January 1, 2018, Adel Al-Saleh was CEO of Northgate Information Solutions Group where he developed a turnaround strategy and drove a successful value creation program across Northgate’s three businesses. Prior to joining Northgate in 2011, Adel held various senior executive positions at IMS Health (market leader in healthcare informatics) and spent the first 19 years at IBM, holding a variety of senior leadership roles.
Mr. Frédéric Duchesne serves as the Chief Executive Officer of the Pharmaceuticals Division of Pierre Fabre, serving patients in more than 130 countries. He also serves as Managing Director Pharmaceutics of Pierre Fabre Investment Arm and is a Member of the Board of the European Federation of Pharmaceutical Industries and Associations (EFPIA). Prior to joining Pierre Fabre in 2010, Frédéric held senior executive positions at GSK in the UK and France.
Mr. Bernard Gilly, Ph.D. has over twenty years of experience in the financial and biotech sectors. He co-founded several disruptive technologies start-ups and is currently Chairman of Pixium Vision (2011), EyeTechCare (2012), Gecko Biomedical (2013) and Chronocam (2015). From 2005 to 2009, he founded and was Chairman and Chief Executive Officer of Fovea Pharmaceuticals, a privately owned biotech company, which was acquired by sanofi in 2009. After the acquisition, he became Senior Vice-President of the Ophthalmology Division of Sanofi until 2012. Prior to Fovea, Dr. Gilly was a partner at Sofinnova Partners from 2000 to 2005.
Embleema’s Advisory Board will provide strategic guidance to the company in terms of assessing the healthcare and technology markets, identifying growth opportunities, and defining strategic and tactical plans.
About Embleema Inc.
Embleema Inc. is a healthcare technology company based in New York, applying blockchain technology for the benefit of patients. Its first blockchain platform PatientTruth allows patients to securely store and control their longitudinal medical history and drive a new decentralized health economy. As chair of the Linux Hyperledger Healthcare Working Group, Embleema is fully committed to drive standards for open-source healthcare blockchain software allowing mass adoption of PatientTruth by the entire healthcare ecosystem, including patient advocacy groups, payers, providers, healthcare product manufacturers, and healthcare authorities.
Disclaimer: The opinions expressed in this article do not represent the views of NewsBTC or any of its team members. NewsBTC is not responsible for the accuracy of any of the information supplied in Sponsored Stories/Press Releases such as this one.